Document:

Exhibit
10.5

 

DEBT
MODIFICATION AGREEMENT

 

THIS
DEBT MODIFICATION AGREEMENT (this “Agreement”) is entered into as of August 30, 2022, by and among, Progressive
Care Inc., a Delaware corporation (the “Company”) and NextPlat Corp, a Nevada corporation (“NextPlat”),
Charles Fernandez (“Fernandez”), Rodney Barreto (“Barreto”), Daniyel Erdberg (“Erdberg”),
and Sixth Borough Capital Fund LP, a Delaware limited partnership (“6B”, and together with NextPlat, Barreto,
Fernandez and Erdberg, the “Purchasers”), each a “Party” and collectively the “Parties”,
upon the following premises:

 

WHEREAS,
On March 6, 2019, Company sold and issued to Iliad Research and Trading, L.P., a Utah limited partnership (“Iliad”)
a certain Secured Convertible Promissory Note in the original principal amount of $3,310,000.00 (the “Iliad Note”)
pursuant to a certain Securities Purchase Agreement between Company and Iliad (the “Iliad Purchase Agreement,”
and together with the Iliad Note, and all other documents entered into in conjunction therewith (the “Iliad Financing Documents”);

 

WHEREAS,
on January 20, 2022, Iliad and the Company entered into that certain Settlement Agreement, Waiver And Release of Claims (the “Iliad
Settlement Agreement”) which inter alia modified the terms of such Note;

 

WHEREAS,
as of the date of this Agreement, the aggregate amount of principal and interest outstanding under the Iliad Note is $2,790,885.63;

 

WHEREAS,
in consideration of the Purchasers agreement to reduce the interest rate under the Iliad Note and to fix the conversion price of the
Iliad Note, the Company has agreed to issue 21,000,000 shares of its Common Stock to the Purchaser pro rata in proportion to the
amount of the consideration paid by each Purchaser under the NPA (defined below);

 

WHEREAS,
Purchasers have entered into a Confidential Securities Purchase And Release Agreement with Iliad and the Company dated August 30, 2022
inter alia pursuant to which the Purchasers have agreed purchase the Iliad Note from Iliad (the “NPA”),
and NextPlat has entered into a Securities Purchase Agreement dated August 30, 2022 (the “SPA”) to purchase
equity securities to be issued by the Company;

 

WHEREAS,
the Purchasers and the Company wish to modify the terms of the Iliad Note, and the Company has induced the Purchasers to enter into
the NPA and the SPA by offering to modify the Iliad Note as contemplated by this Agreement;

 

WHEREAS,
the Purchasers require that the Company obligate itself to modify the terms of the Iliad Note in advance of the Purchasers closing
under the SPA and the NPA; and

 

WHEREAS,
the Parties intend that this Agreement become effective contemporaneously with the date and time of the NPA and SPA (the “Effective
Date”);

 

    	 

    	 

    

 

NOW
THEREFORE, on the stated premises and for and in consideration of the mutual covenants and agreements hereinafter set forth and the
mutual benefits to the Parties to be derived herefrom, and for other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, it is hereby agreed as follows:

 

ARTICLE
I

DEFINITIONS

 

Each
of the foregoing recitals is incorporated herein and together form part of this Agreement.

 

Section
1.1 Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the
following terms have the meanings set forth in this Section 1.1:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act, or is serving as counsel to such Person;
without limiting the foregoing the term “Affiliate” shall with respect to a limited liability company, corporation, or partnership,
include parent and subsidiary corporations, liability companies, corporations, or partnership divisions, shareholders, members, managers,
predecessors, successors and assigns, officers, directors, trustees, fiduciaries, managers, administrators, agents, attorneys, insurers
and representatives.

 

“Effective
Date” has the meaning set forth in the recitals to this Agreement.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.

 

“Securities
Act shall mean the Securities Act of 1933, as amended.

 

ARTICLE
II

COMPANY
ISSUANCE OF COMMON STOCK 

 

Section
2.1 Commitment Shares. At the Effective Date, the Company will issue 21,000,000 shares of its Common Stock (the
“Commitment Shares”) to the Purchaser pro rata in accordance with the amount of the consideration
paid by each Purchaser under the NPA in consideration inter alia of the Purchasers’ agreement to reduce the interest rate
under the Iliad Note and to fix the conversion price of the Iliad Note.

 

    	2

    	 

    

 

ARTICLE
III

REPRESENTATIONS,
COVENANTS, AND WARRANTIES OF THE COMPANY

 

Section
3.1 Company Representation and Warranties.

 

Company
hereby makes the following representations and warranties to each of the Purchasers:

 

(a) Authorization;
Enforcement. It has the requisite corporate power and authority to enter into and to consummate this Agreement and the transactions
contemplated by this Agreement and otherwise to carry out its obligations thereunder. The execution and delivery of this Agreement by
it and the consummation by it of the transactions contemplated thereby have been duly authorized by all necessary action on its part
and no further action is required by it in connection therewith. This Agreement has been (or upon delivery will have been) duly executed
by it and, when delivered in accordance with the terms hereof, will constitute its valid and binding obligation enforceable against it
in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies or by other
equitable principles of general application.

 

(b) No
Conflicts. The execution, delivery and performance of this Agreement by it and the consummation by it of the transactions contemplated
thereby do not and will not (i) conflict with or violate any provision of the it’s certificate or articles of incorporation, bylaws
or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of
time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation (with
or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument or other understanding to which
it is a party or by which any of its property or assets is bound or affected, or (iii) be subject to any consent, waiver, authorization
or order of, give any notice to, or make any filing or registration with, any United States court or other federal, state, local or other
governmental authority or other Person in connection with its execution, delivery and performance under this Agreement, that could result
in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority
to which it is subject (including federal and state securities laws and regulations), or by which any of its property or assets is bound
or affected.

 

(c) Filings,
Consents and Approvals. It is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make
any filing or registration with, any federal, state, local or other governmental authority or other Person, or any court or other federal,
state, local or other governmental authority or other Person in connection with the execution, delivery and performance by this Agreement.

 

(d) Representations
and Warrants Set Forth in the SPA. Company hereby makes the representations, warranties and covenants set forth in the SPA, which
representations, warranties and covenants are incorporated herein by reference.

 

    	3

    	 

    

 

ARTICLE
IV

REPRESENTATIONS
AND WARRANTIES OF PURCHASERS

 

Section
4.1 Purchasers Representations and Warranties. As an inducement to, and to obtain the reliance of the Company,

 

(a) Authority.
Each of the Purchasers represents and warrants to Company that it has the power and is duly authorized, qualified, franchised, and licensed
under all applicable laws, regulations, ordinances, and orders of public authorities to enter into this Agreement.

 

(b) Own
Account. Such Purchaser understands that the Commitment Shares are “restricted securities” and have not been registered
under the Securities Act or any applicable state securities law and is acquiring the Commitment Shares as principal for its own account
and not with a view to or for distributing or reselling such Commitment Shares or any part thereof in violation of the Securities Act
or any applicable state securities law, has no present intention of distributing any of such Commitment Shares in violation of the Securities
Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute
or regarding the distribution of such Commitment Shares in violation of the Securities Act or any applicable state securities law (this
representation and warranty not limiting such Purchaser’s right to sell the Commitment Shares pursuant to the Registration Statement
or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Commitment Shares hereunder
in the ordinary course of its business.

 

(c) Purchaser
Status. At the time such Purchaser was offered the Commitment Shares, it was, and as of the date hereof it is, (i) an “accredited
investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act or
(ii) a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act.

 

(d) Experience
of Such Purchaser. Such Purchaser, either alone or together with its representatives, has knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Commitment
Shares, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment
in the Commitment Shares and, at the present time, is able to afford a complete loss of such investment.

 

(e) General
Solicitation. Such Purchaser is not, to such Purchaser’s knowledge, purchasing the Commitment Shares as a result of any advertisement,
article, notice or other communication regarding the Commitment Shares published in any newspaper, magazine or similar media or broadcast
over television or radio or presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general
advertisement.

 

(f) Access
to Information. Such Purchaser acknowledges that it has been afforded (i) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the
Commitment Shares and the merits and risks of investing in the Commitment Shares; (ii) access to information about the Company and its
financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment;
and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort
or expense that is necessary to make an informed investment decision with respect to the investment.

 

    	4

    	 

    

 

The
Company acknowledges and agrees that the representations contained in this Section 4.1 shall not modify, amend or affect such Purchaser’s
right to rely on the Company’s representations and warranties contained in this Agreement or any other document or instrument executed
and/or delivered in connection with this Agreement or the consummation of the transactions contemplated hereby.

 

ARTICLE
V

Modification
of the Iliad Note

 

Section
5.1 Modification of the Iliad Note.

 

Effective
on the Effective Date, the Company shall modify the Iliad Note as follows and shall reissue an amended and restated note (the “Amended
and Restated Note”) to the Purchasers reflecting the following modifications (capitalized terms not defined in this Agreement
shall have the meanings set forth in the Iliad Note):

 

(a) The
Maturity Date set forth in the Iliad Note shall be modified to August 31, 2027.

 

(b) Outstanding
Balance shall bear interest at the simple annual rate of five percent (5%) per annum from the Effective Date until the same is paid in
full.

 

(c) Section
1.2 of the Iliad Note shall be deleted, and the Amended and Restated Note shall reflect that the Company is prohibited from prepaying
the Note.

 

(d) Section
3.1 shall be amended and restated to read:

 

“Subject
to the adjustments set forth herein, the conversion price for each Conversion (as defined below) shall be $0.02 per share of Common Stock
(the “Conversion Price”).”

 

(e) The
first sentence of Section 3.2 shall be amended and restated to read:

 

“Each
Lender shall have the right, exercisable at any time in its sole and absolute discretion, to redeem all or any portion of the Note (such
amount, the “Redemption Amount”) by providing Borrower with a notice substantially in the form attached hereto as Exhibit
A (each, a “Redemption Notice”, and each date on which Lender delivers a Redemption Notice, a “Redemption Date”).

 

(f) Sections
5.1, 5.2 and 5.3 of the Iliad Note shall be deleted in their entirety.

 

(g) The
Note shall provide for mandatory conversion upon the later to occur of: (a) the completion of the Company’s reverse stock split
as set forth in the SPA, and (b) the listing of the Company’s Common Stock on a national exchange, including the Nasdaq Capital
Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange.

 

    	5

    	 

    

 

(g) The
Amended and Restated Note will reflect that four separate Purchasers are purchasing the Amended and Restated Note, and each will have
the status of “Lender.”

 

(h) The
Amended and Restated Note will reflect that NextPlat will have the sole right to modify, amend, or waive the terms of the Amended and
Restated Note or issue a consent thereunder, and that any such modification, amendment, waiver or consent shall be binding upon all of
the Lenders.

 

ARTICLE
VI

Authorization;
Enforcement.

NON-DISCLOSURE

 

Section
6.1 Non-Disclosure. Each Purchaser agrees that neither it nor any of its Affiliates will disclose or use for its benefit or
the benefit of any other Person, any information regarding the Company and received prior to the date of this Agreement or pursuant to
this Agreement that (i) has not been disclosed publicly by Company, (ii) is otherwise not a matter of public knowledge, and that such
Purchaser will not engage in any market transactions in the securities of Company until the existence of this Agreement, the SPA and
the NPA have been publicly disclosed by Company. Company agrees to promptly disclose the existence and terms of this Agreement, the SPA
and the NPA promptly following the Effective Date.

 

Section
6.2 Confidentiality of this Agreement. Each Party agrees to, and to cause its Affiliates to, keep secret and strictly
confidential the terms of this Agreement and further represents and warrants that it will not disclose, make known, discuss or relay
any information concerning this Agreement, or any of the discussions leading up to this Agreement, to anyone (other than its
accountant, tax advisor or attorney who have first agreed to keep said information confidential and not to disclose it to others),
and that it has not done so as of the Effective Date. The foregoing shall not prohibit or restrict such disclosure as required by
law or as may be necessary for the prosecution of claims relating to the performance or enforcement of this Agreement or prohibit or
restrict any Party (or its attorney) from responding to any such inquiry about this separation or its underlying facts and
circumstances by any governmental organization. Prior to making any disclosure other than to its accountants, tax advisors or
attorneys, a Purchaser shall provide the Company with as much notice as possible that it has been requested or compelled to make
disclosure and use its best efforts to ensure that if such disclosure occurs it does so in a manner designed to fully maintain the
confidentiality of this Agreement.

 

ARTICLE
VII

MISCELLANEOUS

 

Section
7.1 Further Assurances. Each Party shall, and shall cause its Affiliates to, cooperate with each other in the taking of all
actions necessary, proper or advisable under this Agreement and applicable laws to effectuate the purposes contemplated by this Agreement.

 

    	6

    	 

    

 

Section
7.2 Governing Law and Venue. This Agreement will be deemed to have been made and delivered in the State of New York, and both
the binding provisions of this Agreement and the transactions contemplated hereby will be governed as to validity, interpretation,
construction, effect and in all other respects by the internal laws of the State of New York, without regard to the conflict of laws
principles thereof. Each of the Parties: (i) agrees that any legal suit, action or proceeding arising out of or relating to
Agreement and/or the transactions contemplated hereby will be instituted exclusively in the courts located in the City of New York,
State of New York, (ii) waives any objection which it may have or hereafter to the venue of any such suit, action or proceeding, and
(iii) irrevocably consents to the exclusive jurisdiction of the state courts located in the City of New York, State of New York, in
any such suit, action or proceeding, waiving any, and agreeing not to assert any, basis for seeking transfer or removal of such
action to any other court, whether federal or state, unless the New York court in which such action or proceeding was commenced
first declines jurisdiction. Each of the Parties further agrees to accept and acknowledge service of any and all process which may
be served in any such suit, action or proceeding in such courts and agrees that service of process upon Party mailed by certified
mail to the Party’s address will be deemed in every respect effective service of process upon that Party.

 

Section
7.3 Entire Agreement. Except as specifically contemplated by this Agreement, this Agreement represent the entire agreement
among the Parties relating to the subject matter thereof and supersedes all prior agreements, term sheets, understandings and negotiations,
written or oral, with respect to such subject matter.

 

Section
7.3 Communication and Notice. All communications hereunder, except as herein otherwise specifically provided, shall be
in writing and shall be mailed (registered or certified mail, return receipt requested), personally delivered or sent by e-mail or facsimile
transmission and confirmed and shall be deemed given when so delivered, e-mailed or faxed and confirmed or if mailed, two (2) days after
such mailing.

 

If
to the Purchasers:

 

NextPlat
Corp

3250
Mary Street

Suite
410

Coconut
Grove, Florida 33133

Attention:
Charles M. Fernandez

Email:
cfernandez@nextplat.com

 

with
a copy (which shall not constitute notice) to:

 

Ralph
V. De Martino, Esquire

Partner

ArentFox
Schiff LLP

1717
K Street NW

Washington,
DC 20006

Email:
ralph.demartino@afslaw.com

 

    	7

    	 

    

 

If
to the Company:

 

400
Ansin Blvd, Suite A

Hallandale
Beach, FL 33009

 

with
a copy (which shall not constitute notice) to:

 

Lucosky
Brookman LLP

101
Wood Avenue South

Woodbridge,
New Jersey 08830

Attention:
Seth Brookman, Esq.

Email:
sbrookman@lucbro.com

 

Section
7.4 Further Assurances. Each Party agrees that it shall take, or cause to be taken, all actions and to do, or cause to be
done, all things necessary, proper or advisable under applicable laws and regulations to consummate and make effective this
Agreement and the transactions contemplated herein.

 

Section
7.5 Remedies. The Parties agree that the covenants and obligations contained in this Agreement relate to special, unique and
extraordinary matters and that a violation of any of the terms hereof or thereof would cause irreparable injury in an amount which would
be impossible to estimate or determine and for which any remedy at law would be inadequate. As such, the Parties agree that if either
Party fails or refuses to fulfill any of its obligations under this Agreement or to make any payment or deliver any instrument required
hereunder or thereunder, then the other Party shall have the remedy of specific performance, which remedy shall be cumulative and nonexclusive
and shall be in addition to any other rights and remedies otherwise available under any other contract or at law or in equity and to
which such Party might be entitled.

 

Section
7.6 Construction. The Parties acknowledge that each of them has had the benefit of legal counsel of its own choice and has
been afforded an opportunity to review this Agreement with its legal counsel and that this Agreement shall be construed as if jointly
drafted by the Parties hereto. In this Agreement, the word “include”, “includes”, “including”
and “such as” are to be construed as if they were immediately followed by the words, without limitation.

 

Section
7.7 Severability. The invalidity or unenforceability of any term, phrase, clause, paragraph, restriction, covenant, agreement
or other provision of this Agreement shall in no way affect the validity or enforcement of any other provision or any part
thereof.

 

Section
7.8 Headings; Gender. The paragraph headings contained in this Agreement are for convenience only and shall in no manner be
construed as part of this Agreement. All references in this Agreement as to gender shall be interpreted in the applicable gender of the
Parties.

 

Section
7.9 Counterparts; Effect of Facsimile and Photocopied Signatures. This Agreement may be executed in several counterparts,
each of which is an original. It shall not be necessary in making proof of this Agreement or any counterpart hereof to produce or
account for any of the other counterparts. A copy of this Agreement signed by one Party and faxed or scanned and emailed to another
Party (as a PDF, DocuSign or similar image file) shall be deemed to have been executed and delivered by the signing Party as though
an original. A photocopy or PDF of this Agreement shall be effective as an original for all purposes.

 

[Remainder
of page left intentionally blank. Signature page follows.]

 

    	8

    	 

    

 

IN
WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the date first-above written.

 

	PURCHASERS:	 
	 	 	 
	NextPlat Corp	 
	 	 	 
	By:	/s/ Charles M. Fernandez	 
	Name: 	Charles M. Fernandez	 
	Title:	 Chief Executive Officer	 

 

	Sixth Borough Capital Fund, LP	 
	 	 	 
	By: 	/s/ Robert D. Keyser	 
	Name: 	Robert D. Keyser	 
	Title: 	Chief Executive Officer	 

 

	Charles Fernandez, Individually	 
	 	 
	/s/ Charles M. Fernandez	 
	 	 
	Rodney Barreto, Individually	 
	 	 
	/s/ Rodney Barreto	 
	 	 
	Daniyel Erdberg, Individually	 
	 	 
	/s/ Daniyel Erdberg	 

 

	THE COMPANY:	 
	 	 	 
	Progressive Care, Inc.	 
	 	 	 
	By: 	/s/ Alan Jay Weisberg	 
	Name: 	Alan Jay Weisberg	 
	Title: 	Chief Executive Officer	 

 

    	9Exhibit
10.6

 

 

PLACEMENT
AGENCY AGREEMENT

 

Progressive
Care Inc.

 

400
Ansin Blvd. Suite A.

 

Hallandale
Beach, FL. 33009

 

August
30, 2022

 

Ladies
and Gentlemen:

 

This
letter (this “Agreement”) constitutes the agreement between Progressive Care Inc., a Delaware corporation (the “Company”)
and Dawson James Securities, Inc. (“Dawson” or the “Placement Agent”) pursuant to which Dawson
shall serve as the exclusive placement agent (the “Services”) for the Company, on a best efforts basis, in connection
with the proposed private offering and placement (the “Offering”) by the Company of Units of the Company’s Series
B Preferred Stock (the “Preferred Stock”) and warrants (the “Warrants”) to purchase Series B Preferred
Stock (the “Securities” or the “Units”)), and pursuant to which Dawson would act as placement agent
and advisor in connection with the resale of approximately $2.8 million face amount of debt held by Iliad Research & Trading, L.P.
to be sold (and renegotiated with the Company) contemporaneously with the Offering. The Company and Dawson hereby mutually agree to the
terms of the Offering, the debt as modified (the “Debt”) and the Securities, and nothing in this Agreement may be
construed to suggest that Dawson would have the power or authority to bind the Company or an obligation for the Company to issue any
Securities or complete the Offering. The Company expressly acknowledges and agrees that Dawson’s obligations hereunder are on a
reasonable “best efforts basis” only and that the execution of this Agreement does not constitute a commitment by Dawson
to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Dawson
placing the Securities.

 

    	 

     

    

 

	1.	Appointment
                                            of Dawson James Securities, Inc. as Exclusive Placement Agent.

 

On
the basis of the representations, warranties, covenants and agreements of the Company herein contained, and subject to all the terms
and conditions of this Agreement, the Company hereby appoints the Placement Agent as its exclusive placement agent in connection with
a distribution of its Securities to be offered and sold by the Company in connection with the Offering in reliance upon the exemption
from securities registration afforded by Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”),
and Rule 506(b) of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission
(the “SEC”) under the Securities Act, and Dawson agrees to act as the Company’s exclusive Placement Agent. The
Debt will be transferred in reliance upon exemptions from registration set forth in the Securities Act. Pursuant to this appointment,
the Placement Agent will solicit offers for the purchase of or attempt to place all or part of the Securities of the Company in the proposed
Offering as well as offers to purchase the Debt. Until the final closing or earlier upon termination of this Agreement or expiration
of the Exclusive Term pursuant to Section 5 hereof, the Company shall not, without the prior written consent of the Placement Agent,
solicit or accept offers to purchase the Securities other than through the Placement Agent. The Company acknowledges that the Placement
Agent will act as an agent of the Company and use its reasonable “best efforts” (i) to solicit offers to purchase the Securities
from the Company on the terms, and subject to the conditions, set forth in the Subscription Documents (as defined in Section 3), and
(ii) to solicit offers to purchase the Debt. The Placement Agent shall use commercially reasonable efforts to assist the Company in obtaining
performance by each Purchaser whose offer to purchase Securities has been solicited by the Placement Agent, but the Placement Agent shall
not, except as otherwise provided in this Agreement, be obligated to disclose the identity of any potential purchaser or have any liability
to the Company in the event any such purchase is not consummated for any reason. Under no circumstances will the Placement Agent be obligated
to underwrite or purchase any Securities or the Debt for its own account and, in soliciting purchases of the Securities, the Placement
Agent shall act solely as an agent of the Company. The Placement Agent’s services provided pursuant to this Agreement shall be
on an “agency” basis and not on a “principal” basis.

 

The
Placement Agent will solicit offers for the purchase of the Securities in the Offering and offers to purchase the Debt at such times
and in such amounts as the Placement Agent deems advisable and will communicate to the Company, orally or in writing, each reasonable
offer to purchase Securities received by the Placement Agent as an agent of the Company. The Company shall have the sole right to accept
offers to purchase Securities and may reject any such offer, in whole or in part. The Placement Agent may retain other brokers or dealers
to act as sub-agents on its behalf in connection with the Offering and may pay any sub-agent a solicitation fee with respect to any Securities
placed by it. The Company and Placement Agent shall negotiate the timing and terms of the Offering and acknowledge that the Offering
and the provision of Placement Agent services related to the Offering are subject to market conditions and the receipt of all required
related clearances and approvals.

 

    	2

    	Progressive Care Inc.

    

 

	2.	Fees
                                            and Expenses; Tail; Right of First Refusal.

 

In
connection with the Placement Agent services described above, the Company shall pay to Dawson the following compensation:

 

A. Placement
Agent’s Fee. As compensation for services rendered: (i) the Company shall pay to the Placement Agent in cash by wire transfer
in immediately available funds to an account or accounts designated by the Placement Agent an amount (the “Placement Fee”)
equal to 7% of the aggregate gross proceeds received by the Company from the sale of the Units and 7% of the purchase price of the Debt,
at one or more closings (each a “Closing” and the date on which each Closing occurs, a “Closing Date”);
and (ii) the Company shall issue to the Placement Agent or its designees at each Closing warrants (the “Placement Agent Warrants”)
to purchase that number of shares of Common Stock equal to 10% of the total number of shares of Common Stock of the Company (i) issuable
upon conversion or exercise, respectively, of the Preferred Stock and Warrants sold in the Offering and (ii) the number of shares of
Common Stock into which the Debt may be converted. The Placement Agent Warrants will be exercisable at a price per share equal to $0.02,
will have a five year term, will be immediately exercisable, in whole or in part, on one or more occasions, shall contain registration
rights, and shall contain cashless exercise provisions. The form of warrant will be based upon the form of the Warrants issued in the
Offering. In addition, the Placement Agent shall be paid 6% of the gross exercise proceeds, when, as and if the Warrants are exercised.

 

B.
Offering Expenses. The Company agrees to pay all costs, fees and expenses incurred by the Company in connection with the performance
of its obligations hereunder and in connection with the transactions contemplated hereby, including, without limitation: (a) all actual
fees, expenses and disbursements relating to the Securities under the “blue sky” securities laws of such states and other
jurisdictions as the Placement Agent may reasonably designate; (b) the costs of all mailing and printing of the Subscription Documents
and all amendments, supplements and exhibits thereto as the Placement Agent may reasonably deem necessary; (c) the costs of preparing,
printing and delivering certificates representing the Securities; (d) fees and expenses of the transfer agent for the Securities; (e)
the fees and expenses of the Company’s accountants; (f) the fees and expenses of the Company’s legal counsel and other agents
and representatives; and (g) the legal and diligence fees and expenses of the Placement Agent not to exceed $125,000.00.The Placement
Agent may deduct from the net proceeds of the Offering payable to the Company on the Closing Date, the expenses set forth herein to be
paid by the Company to the Placement Agent, provided, however, that in the event that the Offering is terminated, the Company agrees
to reimburse the Placement Agent pursuant to Section 5 hereof.

 

    	3

    	Progressive Care Inc.

    

 

C. If
the Offering is completed, the Company will provide the Placement Agent a right of first refusal to act as lead placement agent on any
and all private or public offerings of debt or equity or other securities of the Company (or use commercially reasonable efforts to have
the Placement Agent selected as a co-managing underwriter) for a period of twelve (12) months from the final Closing (“Exclusivity
Period”).

 

D. If
the Offering is completed, the Placement Agent shall be entitled to all fees per this section with respect to any public or private offering
or other financing or capital-raising transaction of any kind (“Tail Financing”) to the extent that such financing
or capital is provided to the Company by investors whom the Placement Agent had introduced to the Company during the term of this Agreement,
if such Tail Financing is consummated at any time during the Exclusivity Period. Within three days following termination or expiration
of this Agreement, the Placement Agent shall provide a list of investors to the Company for review which the Company may reasonably reject
inclusion of specific investor. In no event shall such list include persons that are existing shareholders unless they have invested
into the Company through the Placement Agent in the past.

 

	3.	[RESERVED]

 

	4.	Delivery
                                            and Payment; Closing.

 

Payment
for, and delivery of the Securities and the Debt will be arranged directly between the Company and the Investors. Each Closing shall
occur at such place as shall be agreed upon by the Placement Agent and the Company. In the absence of an agreement to the contrary, each
Closing shall take place at the offices of Schiff Hardin LLP, 901 K Street, NW, Suite 700, Washington, DC 20001. Deliveries of the documents
with respect to the purchase of the Securities, if any, shall be made at the offices of Schiff Hardin, LLP, 901 K Street, NW, Suite 700,
Washington, DC 20001 on each Closing Date. All actions taken at a Closing shall be deemed to have occurred simultaneously.

 

    	4

    	Progressive Care Inc.

    

 

	5.	Term
                                            and Termination of Agreement.

 

The
term of this Agreement will commence upon the execution of this Agreement and will terminate on the final Closing of the Offering or
11:59 p.m. (New York Time) (the “Exclusive Term”). Notwithstanding anything to the contrary contained herein, any
provision in this Agreement concerning or relating to confidentiality, indemnification, contribution, advancement, the Company’s
representations and warranties and the Company’s obligations to pay fees and reimburse expenses will survive any expiration or
termination of this Agreement. If any condition specified in Section 8 is not satisfied when and as required to be satisfied, this Agreement
may be terminated by the Placement Agent by notice to the Company at any time on or prior to a Closing Date, which termination shall
be without liability on the part of any party to any other party, except that those portions of this Agreement specified in Section 19
shall at all times be effective and shall survive such termination. Notwithstanding anything to the contrary in this Agreement, in the
event that this Agreement shall not be carried out for any reason whatsoever, within the time specified herein or any extensions thereof
pursuant to the terms herein, the Company shall be obligated to pay to the Placement Agent their actual and accountable out-of-pocket
expenses related to the transactions contemplated herein then due and payable and upon demand the Company shall pay the full amount thereof
to the Placement Agent; provided, that the legal and diligence fees and expenses of the Placement Agent shall not exceed $125,000.00,
if the Offering is not completed; and provided, however, that such expense cap in no way limits or impairs the indemnification and contribution
provisions of this Agreement.

 

	6.	Permitted
                                            Acts.

 

Nothing
in this Agreement shall be construed to limit the ability of the Placement Agent, its officers, directors, employees, agents, associated
persons and any individual or entity “controlling,” controlled by,” or “under common control” with the
Placement Agent (as those terms are defined in Rule 405 under the Securities Act) to conduct its business including without limitation
the ability to pursue, investigate, analyze, invest in, or engage in investment banking, financial advisory or any other business relationship
with any individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

    	5

    	Progressive Care Inc.

    

 

	7.	Representations,
                                            Warranties and Covenants of the Company.

 

As
of the date and time of the execution of this Agreement and each Closing Date, the Company represents, warrants and covenants to the
Placement Agent that:

 

A.
SEC Reports; Financial Statements, etc. Except as set forth on Schedule 7.A, the Company has complied in all material respects
with requirements to file all reports, schedules, forms, statements and other documents required to be filed by it under the Securities
Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including pursuant to Section 13(a)
or 15(d) thereof, for the 24 months preceding the date hereof (or such shorter period as the Company was required by law to file such
material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively
referred to herein as the “SEC Reports”) on a timely basis or has received a valid extension of such time of filing
and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied
in all material respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations of the Commission
promulgated thereunder, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state
a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material
respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at
the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles
(“GAAP”) applied on a consistent basis during the periods involved, except as may be otherwise specified in such financial
statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly
present in all material respects the financial position of the Company and its consolidated subsidiaries as of and for the dates thereof
and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial,
year-end audit adjustments. The financial statements, including the notes thereto and supporting schedules, included in the Subscription
Documents fairly present in all material respects the financial position and the results of operations of the Company at the dates and
for the periods to which they apply; and such financial statements have been prepared in conformity with GAAP, consistently applied throughout
the periods involved (provided that unaudited interim financial statements are subject to year-end audit adjustments that are not expected
to be material in the aggregate and do not contain all footnotes required by GAAP). The pro forma and pro forma as adjusted financial
information and the related notes, if any, included in the SEC Reports have been properly compiled and prepared in accordance with the
applicable requirements of the Securities Act and the rules and regulations thereto (the “Securities Act Regulations”)
and present fairly in all material respects the information shown therein, and the assumptions used in the preparation thereof are reasonable
and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein. All disclosures
contained in the Subscription Documents regarding “non-GAAP financial measures” (as such term is defined by the rules and
regulations of the Commission), if any, comply with Regulation G of the Exchange Act to the extent applicable. Except as disclosed in
the SEC Reports included in the Subscription Documents, (a) the Company has not incurred any material liabilities or obligations, direct
or contingent, or entered into any material transactions other than in the ordinary course of business, (b) the Company has not declared
or paid any dividends or made any distribution of any kind with respect to its capital stock, (c) there has not been any change in the
capital stock of the Company, or, other than in the ordinary course of business, any grants under any stock compensation plan, and (d)
there has not been any change in the Company’s long-term or short-term debt that, singularly or in the aggregate, would involve
a material adverse change or a prospective material adverse change, in or affecting the condition (financial or otherwise), results of
operations, business, assets or prospects of the Company (a “Material Adverse Change”).

 

B.
Independent Accountants. To the knowledge of the Company, Daszkal Bolton LLP (the “Auditors”), whose reports
are filed with the Commission, is an independent registered public accounting firm as required by the Securities Act and the Securities
Act Regulations and the Public Company Accounting Oversight Board.

 

    	6

    	Progressive Care Inc.

    

 

C.
Authorized Capital, etc. The Company’s duly authorized, issued and outstanding capitalization is set forth in the Subscription
Documents. Based on the assumptions stated in the Subscription Documents, the Company will have the adjusted stock capitalization within
the time period pursuant to the terms set forth therein. Except as set forth in the Subscription Documents, as of each Closing Date,
there will be no stock options, warrants, or other rights to purchase or otherwise acquire any authorized, but unissued shares of Common
Stock of the Company or any security convertible or exercisable into shares of Common Stock of the Company, or any contracts or commitments
to issue or sell shares of Common Stock or any such options, warrants, rights or convertible securities.

 

D. Valid
Issuance of Securities, etc.

 

		i.	Outstanding
                                            Securities. All issued and outstanding securities of the Company issued prior to the
                                            transactions contemplated by this Agreement have been duly authorized and validly issued
                                            and are fully paid and non-assessable; the holders thereof have no rights of rescission with
                                            respect thereto, and are not subject to personal liability by reason of being such holders;
                                            and none of such securities were issued in violation of the preemptive rights of any holders
                                            of any security of the Company or similar contractual rights granted by the Company. The
                                            authorized shares of Common Stock, Company preferred stock and other outstanding securities
                                            conform in all material respects to all statements relating thereto contained in the Subscription
                                            Documents. The offers and sales of the outstanding shares of Common Stock were at all relevant
                                            times either registered under the Securities Act and the applicable state securities or “blue
                                            sky” laws or, based in part on the representations and warranties of the purchasers
                                            of such shares, exempt from such registration requirements

 

		ii.	Securities
                                            Sold Pursuant to this Agreement. The Securities have been duly authorized for issuance
                                            and sale and, when issued and paid for, will be validly issued. The Common Stock underlying
                                            the Debt, Preferred Stock, Warrants and Placement Agent Warrants has been duly authorized
                                            for issuance and sale and, when issued and paid for, will be validly issued, fully paid and
                                            non-assessable; the holders of the Securities are not and will not be subject to personal
                                            liability by reason of being such holders; the Securities are not and will not be subject
                                            to the preemptive rights of any holders of any security of the Company or similar contractual
                                            rights granted by the Company; and all corporate action required to be taken for the authorization,
                                            issuance and sale of the Securities has been duly and validly taken. The Securities conform
                                            in all material respects to all statements with respect thereto contained in the Subscription
                                            Documents.

 

E. Registration
Rights of Third Parties. Except as set forth in the Subscription Documents, no holders of any securities of the Company or any rights
exercisable for or convertible or exchangeable into securities of the Company have the right to require the Company to register any such
securities of the Company under the Securities Act or to include any such securities in a registration statement to be filed by the Company.

 

    	7

    	Progressive Care Inc.

    

 

F.
Validity and Binding Effect of Agreements. This Agreement and each subscription agreement to be entered into with each Investor
has been duly and validly authorized by the Company, and, when executed and delivered, will constitute, the valid and binding agreements
of the Company, enforceable against the Company in accordance with their respective terms, except: (i) as such enforceability may be
limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally; (ii) as enforceability
of any indemnification or contribution provision may be limited under the federal and state securities laws; and (iii) that the remedy
of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion
of the court before which any proceeding therefor may be brought.

 

G.
No Conflicts, etc. Except as set forth in Schedule 7G, the execution, delivery and performance by the Company of this Agreement,
the consummation by the Company of the transactions herein contemplated and the compliance by the Company with the terms hereof do not
and will not, with or without the giving of notice or the lapse of time or both: (i) result in a material breach of, or conflict with
any of the terms and provisions of, or constitute a material default under, or result in the creation, modification, termination or imposition
of any lien, charge or encumbrance upon any property or assets of the Company pursuant to the terms of any agreement or instrument to
which the Company is a party; (ii) result in any violation of the provisions of the Company’s Certificate of Incorporation (as
the same may be amended or restated from time to time, the “Charter”) or the by-laws of the Company; or (iii) violate
any existing applicable law, rule, regulation, judgment, order or decree of any governmental agency or court, domestic or foreign, having
jurisdiction over the Company or any of its assets or businesses (each, a “Governmental Entity”) as of the date hereof.

 

H.
No Defaults; Violations. Except as set forth on Schedule 7 (H), the Subscription Documents, no material default exists in the
due performance and observance of any term, covenant or condition of any material license, contract, indenture, mortgage, deed of trust,
note, loan or credit agreement, or any other agreement or instrument evidencing an obligation for borrowed money, or any other material
agreement or instrument to which the Company is a party or by which the Company may be bound or to which any of the properties or assets
of the Company is subject. The Company is not (i) in violation of any term or provision of its Charter or by-laws, or (ii) in violation
of any franchise, license, permit, applicable law, rule, regulation, judgment or decree of any Governmental Entity applicable to the
Company.

 

    	8

    	Progressive Care Inc.

    

 

I. Corporate
Power; Licenses; Consents.

 

		i.	Conduct
                                            of Business. The Company and its subsidiaries each has all requisite corporate power
                                            and authority, and has all necessary authorizations, approvals, orders, licenses, certificates
                                            and permits of and from all governmental regulatory officials and bodies that it needs as
                                            of the date hereof to conduct its business purpose as described in the Subscription Documents.

 

		ii.	Transactions
                                            Contemplated Herein. The Company has all corporate power and authority to enter into
                                            this Agreement and to carry out the provisions and conditions hereof, and all consents, authorizations,
                                            approvals and orders required in connection therewith have been obtained. No consent, authorization
                                            or order of, and no filing with, any court, government agency or other body is required for
                                            the valid issuance, sale and delivery of the Securities and the consummation of the transactions
                                            and agreements contemplated by this Agreement and as contemplated in the Subscription Documents,
                                            except with respect to applicable federal and state securities laws.

 

J.
Litigation; Governmental Proceedings. Except as set forth on Schedule 7(J), there is no action, suit, proceeding, inquiry,
arbitration, investigation, litigation or governmental proceeding pending or, to the Company’s knowledge, threatened against, or
involving the Company which has not been disclosed in the Subscription Documents except any which, singularly or in the aggregate, would
not have or reasonably be expected to result in a Material Adverse Change.

 

K.
Good Standing. The Company has been duly organized and is validly existing as a corporation and is in good standing under the
laws of the State of Delaware as of the date hereof, and is duly qualified to do business and is in good standing in each other jurisdiction
in which its ownership or lease of property or the conduct of business requires such qualification, except where the failure to qualify,
singularly or in the aggregate, would not have or reasonably be expected to result in a Material Adverse Change.

 

    	9

    	Progressive Care Inc.

    

 

L. Insurance.
Except as set forth on Schedule 7 (L), the Company carries or is entitled to the benefits of insurance, with, to the Company’s
knowledge, reputable insurers, and in such amounts and covering such risks which the Company believes are reasonably adequate, and all
such insurance is in full force and effect. The Company has no reason to believe that it will not be able (i) to renew its existing insurance
coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate
to conduct its business as now conducted and at a cost that would not result in a Material Adverse Change.

 

M.
Foreign Corrupt Practices Act. Neither the Company nor, to the Company’s knowledge, any director, officer, agent, employee
or affiliate of the Company or any other person acting on behalf of the Company, has, directly or indirectly, given or agreed to give
any money, gift or similar benefit (other than legal price concessions to customers in the ordinary course of business) to any customer,
supplier, employee or agent of a customer or supplier, or official or employee of any governmental agency or instrumentality of any government
(domestic or foreign) or any political party or candidate for office (domestic or foreign) or other person who was, is, or may be in
a position to help or hinder the business of the Company (or assist it in connection with any actual or proposed transaction) that (i)
might subject the Company to any damage or penalty in any civil, criminal or governmental litigation or proceeding, (ii) if not given
in the past, might have had a Material Adverse Change or (iii) if not continued in the future, might adversely affect the assets, business,
operations or prospects of the Company. The Company has taken reasonable steps to ensure that its accounting controls and procedures
are sufficient to cause the Company to comply in all material respects with the Foreign Corrupt Practices Act of 1977, as amended.

 

N.
Compliance with OFAC. Neither of the Company nor, to the Company’s knowledge, any director, officer, agent, employee or
affiliate of the Company or any other person acting on behalf of the Company, is currently subject to any U.S. sanctions administered
by the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”), and the Company will not,
directly or indirectly, use the proceeds of the Offering hereunder, or lend, contribute or otherwise make available such proceeds to
any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person currently
subject to any U.S. sanctions administered by OFAC.

 

    	10

    	Progressive Care Inc.

    

 

O.
Money Laundering Laws. The operations of the Company are and have been conducted at all times in compliance with applicable financial
recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering
statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines,
issued, administered or enforced by any Governmental Entity (collectively, the “Money Laundering Laws”); and no action,
suit or proceeding by or before any Governmental Entity involving the Company with respect to the Money Laundering Laws is pending or,
to the knowledge of the Company, threatened.

 

P.
Officers’ Certificate. Any certificate signed by any duly authorized officer of the Company and delivered to Dawson or to
Placement Agent Counsel shall be deemed a representation and warranty by the Company to the Placement Agents as to the matters covered
thereby.

 

Q.
Subsidiaries. Except as disclosed in the Subscription Documents, the Company has no direct or indirect subsidiaries.

 

R.
Related Party Transactions. There are no business relationships or related party transactions involving the Company or any other
person required to be described in the SEC Reports that have not been described as required.

 

S.
Board of Directors. The qualifications of the persons serving as members of the Company’s board of director and the overall
composition of the Company’s board of directors comply with the Exchange Act, the rules and regulations thereunder (the “Exchange
Act Regulations”), the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder (the “Sarbanes-Oxley Act”)
applicable to the Company.

 

T. Sarbanes-Oxley
Compliance.

 

		i.	Disclosure
                                            Controls. Except as set forth on Schedule 7(T) (i), the Company has developed
                                            and currently maintains disclosure controls and procedures that will comply with Rule 13a-15
                                            or 15d-15 under the Exchange Act Regulations applicable to it, and such controls and procedures
                                            are effective to ensure that all material information concerning the Company will be made
                                            known on a timely basis to the individuals responsible for the preparation of the Company’s
                                            Exchange Act filings and other public disclosure documents.

 

    	11

    	Progressive Care Inc.

    

 

		ii.	Compliance
                                            The Company is in material compliance with the provisions of the Sarbanes-Oxley Act applicable
                                            to it, and has implemented or will implement such programs and taken reasonable steps to
                                            ensure the Company’s future compliance (not later than the relevant statutory and regulatory
                                            deadlines therefor) with all of the material provisions of the Sarbanes-Oxley Act.

 

U.
Accounting Controls. Except as set forth on Schedule 7(U), the Company maintains systems of “internal control over
financial reporting” (as defined under Rules 13a-15 and 15d-15 under the Exchange Act Regulations) that comply with the requirements
of the Exchange Act and have been designed by, or under the supervision of, its principal executive and principal financial officers,
or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient
to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations;
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset
accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and
(iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken
with respect to any differences. The Company is not aware of any material weaknesses in its internal controls. The Company’s Auditors
and the Audit Committee of the Board of Directors of the Company have been advised of: (i) all significant deficiencies and material
weaknesses, if any, in the design or operation of internal controls over financial reporting which are known to the Company’s management
and that have adversely affected or are reasonably likely to adversely affect the Company’ ability to record, process, summarize
and report financial information; and (ii) any fraud, if any, known to the Company’s management, whether or not material, that
involves management or other employees who have a significant role in the Company’s internal controls over financial reporting.

 

V.
No Investment Company Status. The Company is not and, after giving effect to the Offering and the application of the proceeds
thereof as described in the Subscription Documents, will not be, required to register as an “investment company,” as defined
in the Investment Company Act of 1940, as amended.

 

    	12

    	Progressive Care Inc.

    

 

W.
No Labor Disputes. Except as set forth on Schedule 7(W), no labor dispute with the employees of the Company exists or, to the
knowledge of the Company, is imminent.

 

X.
Intellectual Property Rights. The Company and its subsidiaries own or possess or can acquire on reasonable terms adequate rights
to use all patents, patent rights, licenses, inventions, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable
proprietary or confidential information, systems or procedures), trademarks, service marks, trade names and other intellectual property
(collectively, “Intellectual Property”) necessary to carry on the business of the Company and its subsidiaries (the
“Company Intellectual Property”). Neither the Company nor any subsidiary has received any written notice of any infringement
of, or conflict with any asserted rights of others with respect to any Intellectual Property which would render any Intellectual Property
invalid or inadequate to protect the interest of the Company or any of its subsidiaries. The Company and its subsidiaries have taken
commercially reasonable steps in accordance with normal industry practice to maintain the confidentiality of its trade secrets and other
confidential information, and to secure interests in the Company Intellectual Property developed by their employees, consultants, agents
and contractors in the course of their service to the Company and its subsidiaries. No government funding, facilities or resources of
a university, college, other educational institution or research center or funding from third parties was used in the development of
any Company Intellectual Property that is owned or purported to be owned by the Company or any of its subsidiaries, and no governmental
agency or body, university, college, other educational institution or research center has any claim or right in or to any Company Intellectual
Property that is owned or purported to be owned by the Company or any of its subsidiaries.

 

Y.
Taxes. Except as set forth on Schedule 7(Y), the Company and its subsidiaries each has filed all returns (as hereinafter defined)
required to be filed with taxing authorities prior to the date hereof or has duly obtained extensions of time for the filing thereof.
The Company and its subsidiaries each has paid all taxes (as hereinafter defined) shown as due on such returns that were filed and has
paid all taxes imposed on or assessed against the Company and its subsidiaries. The provisions for taxes payable, if any, shown on the
financial statements filed with or as part of the SEC Reports are sufficient for all accrued and unpaid taxes, whether or not disputed,
and for all periods to and including the dates of such consolidated financial statements. No issues have been raised (and are currently
pending) by any taxing authority in connection with any of the returns or taxes asserted as due from the Company, and no waivers of statutes
of limitation with respect to the returns or collection of taxes have been given by or requested from the Company. The term “taxes”
mean all federal, state, local, foreign and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise,
profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property,
windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatever, together with any interest and any
penalties, additions to tax or additional amounts with respect thereto. The term “returns” means all returns, declarations,
reports, statements and other documents required to be filed in respect to taxes.

 

    	13

    	Progressive Care Inc.

    

 

Z. Employee
Benefit Laws. The operations of the Company and its subsidiaries are and have been conducted at all times in material compliance
with the Employee Retirement Income Security Act of 1974, as amended, the rules and regulations thereunder and any related or similar
rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Employee Benefit
Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator
involving the Company or its subsidiaries with respect to the Employee Benefit Laws is pending or, to the knowledge of the Company, threatened.

 

AA. Compliance
with Laws. The Company and its subsidiaries each: (A) is and at all times has been in compliance with all statutes, rules, or regulations
applicable to its business (“Applicable Laws”), except as would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Change; (B) has not received any correspondence from any Governmental Entity alleging or asserting
noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements
or amendments thereto required by any such Applicable Laws (“Authorizations”); (C) possesses all material Authorizations
and such Authorizations are valid and in full force and effect and the Company is not in material violation of any term of any such Authorizations,
in each case except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change; (D) has
not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action
from any Governmental Entity or third party alleging that any product operation or activity is in violation of any Applicable Laws or
Authorizations and has no knowledge that any such Governmental Entity or third party is considering any such claim, litigation, arbitration,
action, suit, investigation or proceeding; (E) has not received written notice that any Governmental Entity has taken, is taking or intends
to take action to limit, suspend, modify or revoke any Authorizations; and (F) has filed, obtained, maintained or submitted all material
reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable
Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements
or amendments were complete and correct on the date filed (or were corrected or supplemented by a subsequent submission).

 

    	14

    	Progressive Care Inc.

    

 

BB. Industry
Data. The statistical and market-related data included in the Subscription Documents and SEC Reports are based on or derived from
sources that the Company reasonably and in good faith believes are reliable and accurate or represent the Company’s good faith
estimates that are made on the basis of data derived from such sources.

 

CC. Margin
Securities. The Company owns no “margin securities” as that term is defined in Regulation U of the Board of Governors
of the Federal Reserve System (the “Federal Reserve Board”), and none of the proceeds of Offering will be used, directly
or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring any indebtedness
which was originally incurred to purchase or carry any margin security or for any other purpose which might cause any of the shares of
Common Stock to be considered a “purpose credit” within the meanings of Regulation T, U or X of the Federal Reserve Board.

 

DD. Listing.
If after the date hereof the Company obtains a listing of its Common Stock on a national securities exchange, the Company shall use its
commercially reasonable efforts to maintain the listing of the shares of Common Stock (including the Common Stock underlying the Debt,
Preferred Stock and Warrants and Placement Agent Warrants) issued to the Investors and the Placement Agent on such national securities
exchange.

 

EE. Application
of Net Proceeds. The Company shall apply the net proceeds from the Offering received by it in a manner consistent with the application
thereof described under the caption “Summary of the Offering – Use of Proceeds” in the Subscription Documents.

 

    	15

    	Progressive Care Inc.

    

 

FF. Internal
Controls. Except set forth in Schedule 7 (FF), the Company shall use its commercially best effort to cure the identified material
weaknesses and maintain a system of internal accounting controls sufficient to provide reasonable assurances that: (i) transactions are
executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary in order
to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets; (iii) access to assets
is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets
is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

 

GG. No
Fiduciary Duties. The Company acknowledges and agrees that the Placement Agent’s responsibility to the Company is solely contractual
in nature and that neither the Placement Agent nor its affiliates or any selling agent shall be deemed to be acting in a fiduciary capacity,
or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other transactions
contemplated by this Agreement.

 

HH. Blue
Sky Qualifications. The Company shall use its best efforts, in cooperation with the Placement Agent, if necessary, to qualify the
Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as
the Placement Agent may designate and to maintain such qualifications in effect so long as required to complete the distribution of the
Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify
as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation
in respect of doing business in any jurisdiction in which it is not otherwise so subject.

 

II. No
General Solicitation. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has engaged in
any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of
the Securities.

 

    	16

    	Progressive Care Inc.

    

 

JJ. No
Integrated Offering. None of the Company or any of its affiliates, nor any Person acting on their behalf has, directly or indirectly,
made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration
of the issuance of any of the Securities under the Securities Act, whether through integration with prior offerings or otherwise, or
cause this offering of the Securities to require approval of stockholders of the Company under any applicable stockholder approval provisions.
None of the Company, its affiliates, nor any person acting on their behalf will take any action or steps that would require registration
of the issuance of any of the Securities under the Securities Act or cause the offering of any of the Securities to be integrated with
other offerings of securities of the Company.

 

KK. Reservation
of Shares. So long as any of the Debt, Preferred Stock, Warrants or Placement Agent Warrants remain outstanding, the Company shall
take all action necessary to at all times have authorized, and reserved for the purpose of issuance, no less than 130% of the maximum
number of shares of Common Stock issuable upon conversion or exercise of all the Debt, Preferred Stock, Warrants or Placement Agent Warrants
and without regard to any limitations on the conversion of the Preferred Stock, Warrants or Placement Agent Warrants set forth therein

 

LL. Regulation
D Compliance. None of the Company or the Company’s directors, executive officers or, to the Company’s knowledge, its
affiliates is a “bad actor” as defined in Rule 506(d) of the Securities Act.

 

	8.	Conditions
                                            of the Obligations of the Placement Agent.

 

The
obligations of the Placement Agent hereunder shall be subject to the accuracy of the representations and warranties on the part of the
Company set forth in Section 7 hereof, in each case as of the date hereof and as of each Closing Date as though then made, to the timely
performance by each of the Company of its covenants and other obligations hereunder on and as of such dates, and to each of the following
additional conditions:

 

A.
Form D and Blue Sky. The Company shall file a Form D with respect to the Securities as required under Regulation D and to provide
a copy thereof to Placement Agent promptly after such filing. The Company shall, on or before the Closing Date, take such action as the
Company shall reasonably determine is necessary in order to obtain an exemption for, or to, qualify the Securities for sale to the Investors
at the Closing pursuant to this Agreement under applicable securities or “blue sky” laws of the states of the United States
(or to obtain an exemption from such qualification), and shall provide evidence of any such action so taken to the Placement Agent on
or prior to the Closing Date. Without limiting any other obligation of the Company under this Agreement, the Company shall timely make
all filings and reports relating to the offer and sale of the Securities required under all applicable securities laws (including, without
limitation, all applicable federal securities laws and all applicable “blue sky” laws), and the Company shall comply with
all applicable federal, state, local and foreign laws, statutes, rules, regulations and the like relating to the offering and sale of
the Securities to the Investors.

 

    	17

    	Progressive Care Inc.

    

 

B.
Officers’ Certificates.

 

		i.	Officers’
                                            Certificate. The Company shall have furnished to the Placement Agent a certificate, dated
                                            the Closing Date, of its Chief Executive Officer, and its Chief Financial Officer stating
                                            that (i) such officers have carefully examined the Subscription Documents and, in their opinion,
                                            the Subscription Documents as of the Closing Date did not include any untrue statement of
                                            a material fact and did not omit to state a material fact required to be stated therein or
                                            necessary to make the statements therein not misleading, (ii) to their knowledge after reasonable
                                            investigation, as of the Closing Date, the representations and warranties of the Company
                                            in this Agreement are true and correct and the Company has complied with all agreements and
                                            satisfied all conditions on its part to be performed or satisfied hereunder at or prior to
                                            the Closing Date, and (iii) there has not been, subsequent to September 30, 2015, any Material
                                            Adverse Change in the financial position or results of operations of the Company, or any
                                            change or development that, singularly or in the aggregate, would involve a Material Adverse
                                            Change or a prospective Material Adverse Change, in or affecting the condition (financial
                                            or otherwise), results of operations, business, assets or prospects of the Company, except
                                            as set forth in the Subscription Documents.

 

		ii.	Secretary’s
                                            Certificate. At of the Closing Date the Placement Agent shall have received a certificate
                                            of the Company signed by the Secretary of the Company, dated the Closing Date, certifying:
                                            (i) that each of the Charter and Bylaws is true and complete, has not been modified and is
                                            in full force and effect; (ii) that the resolutions of the Company’s Board of Directors
                                            relating to the Offering are in full force and effect and have not been modified; (iii) the
                                            good standing of the Company and its subsidiaries; and (iv) as to the incumbency of the officers
                                            of the Company. The documents referred to in such certificate shall be attached to such certificate.

 

    	18

    	Progressive Care Inc.

    

 

C.
No Material Changes. Since the date of the Subscription Documents, no event or series of events shall have occurred that reasonably
would have or result in a Material Adverse Effect.

 

D.
Additional Documents. At the Closing Date, Placement Agent Counsel shall have been furnished with such documents and opinions
as they may require in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions,
herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Securities as herein contemplated
shall be satisfactory in form and substance to the Placement Agent and Placement Agent Counsel.

 

	9.	Indemnification
                                            and Contribution; Procedures.

 

A.
Indemnification of the Placement Agent. The Company agrees to indemnify and hold harmless the Placement Agent, its affiliates
and each person controlling such Placement Agent (within the meaning of Section 15 of the Securities Act), and the directors, officers,
agents and employees of the Placement Agent, its affiliates and each such controlling person (the Placement Agent, and each such entity
or person hereafter is referred to as an “Indemnified Person”) from and against any losses, claims, damages, judgments,
assessments, costs and other liabilities (collectively, the “Liabilities”), and shall reimburse each Indemnified Person
for all fees and expenses (including the reasonable fees and expenses of counsel for the Indemnified Persons, except as otherwise expressly
provided in this Agreement) (collectively, the “Expenses”) and agrees to advance payment of such Expenses as they
are incurred by an Indemnified Person in investigating, preparing, pursuing or defending any actions, whether or not any Indemnified
Person is a party thereto, arising out of or based upon this Agreement, or arising out of or based upon any untrue statement or alleged
untrue statement of a material fact contained in (i) the Subscription Documents (as from time to time each may be amended and supplemented)
or the Debt purchase agreement; (ii) any materials or information provided to investors by, or with the approval of, the Company in connection
with the marketing of the Offering, including any term sheets or “road show” or investor presentations made to investors
by the Company (whether in person or electronically); or (iii) any application or other document or written communication (in this Section
9, collectively called “application”) executed by the Company or based upon written information furnished by the Company
in any jurisdiction in order to qualify the Securities under the securities laws thereof or to file for an exemption from such requirement
or filed with the Commission, any state securities commission or agency, any national securities exchange; or the omission or alleged
omission therefrom of a material fact required to be stated therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading, unless such statement or omission was made in reliance upon, and in conformity
with, information provided to the Company in writing specifically for use in an application or in the Subscription Documents (the “Placement
Agent’s Information”). The Company also agrees to reimburse each Indemnified Person for all Expenses as they are incurred
in connection with such Indemnified Person’s enforcement of his or its rights under this Agreement.

 

    	19

    	Progressive Care Inc.

    

 

B.
Procedure. Upon receipt by an Indemnified Person of actual notice of an action against such Indemnified Person with respect to
which indemnity may reasonably be expected to be sought under this Agreement, such Indemnified Person shall promptly notify the Company
in writing; provided that failure by any Indemnified Person so to notify the Company shall not relieve the Company from any obligation
or liability which the Company may have on account of this Section 9 or otherwise to such Indemnified Person. The Company shall, if requested
by the Placement Agent, assume the defense of any such action (including the employment of counsel designated by the Placement Agent
and reasonably satisfactory to the Company). Any Indemnified Person shall have the right to employ separate counsel in any such action
and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person
unless: (i) the Company has failed promptly to assume the defense and employ separate counsel designated by the Placement Agent for the
benefit of the Placement Agent and the other Indemnified Persons or (ii) such Indemnified Person shall have been advised that in the
opinion of counsel that there is an actual or potential conflict of interest that prevents (or makes it imprudent for) the counsel designated
by the Placement Agent and engaged by the Company for the purpose of representing the Indemnified Person, to represent both such Indemnified
Person and any other person represented or proposed to be represented by such counsel. The Company shall not be liable for any settlement
of any action effected without its written consent (which shall not be unreasonably withheld). In addition, the Company shall not, without
the prior written consent of the Placement Agent, settle, compromise or consent to the entry of any judgment in or otherwise seek to
terminate any pending or threatened action in respect of which advancement, reimbursement, indemnification or contribution may be sought
hereunder (whether or not such Indemnified Person is a party thereto) unless such settlement, compromise, consent or termination (i)
includes an unconditional release of each Indemnified Person, acceptable to such Indemnified Party, from all Liabilities arising out
of such action for which indemnification or contribution may be sought hereunder and (ii) does not include a statement as to or an admission
of fault, culpability or a failure to act, by or on behalf of any Indemnified Person. The advancement, reimbursement, indemnification
and contribution obligations of the Company required hereby shall be made by periodic payments of the amount thereof during the course
of the investigation or defense, as every Liability and Expense is incurred and is due and payable, and in such amounts as fully satisfy
each and every Liability and Expense as it is incurred (and in no event later than 30 days following the date of any invoice therefore).

 

C.
Indemnification of the Company. The Placement Agent agrees to indemnify and hold harmless the Company, its directors, its executive
officers and persons who control the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act
against any and all Liabilities, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions made
in the Subscription Documents or any amendment or supplement thereto, in reliance upon, and in strict conformity with, the Placement
Agent’s Information. In case any action shall be brought against the Company or any other person so indemnified based on the Subscription
Documents or any amendment or supplement thereto, and in respect of which indemnity may be sought against the Placement Agent, the Placement
Agent shall have the rights and duties given to the Company, and the Company and each other person so indemnified shall have the rights
and duties given to the Placement Agent by the provisions of Section 9.B. The Company agrees promptly to notify the Placement Agent of
the commencement of any litigation or proceedings against the Company or any of its executive officers, directors or any person, if any,
who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, in connection with
the issuance and sale of the Securities or in connection with the Subscription Documents.

 

    	20

    	Progressive Care Inc.

    

 

D.
Contribution. In the event that a court of competent jurisdiction makes a finding that indemnity is unavailable to an Indemnified
Person, the Company shall contribute to the Liabilities and Expenses paid or payable by such Indemnified Person in such proportion as
is appropriate to reflect (i) the relative benefits to the Company, on the one hand, and to the Placement Agent and any other Indemnified
Person, on the other hand, of the matters contemplated by this Agreement or (ii) if the allocation provided by the immediately preceding
clause is not permitted by applicable law, not only such relative benefits but also the relative fault of the Company, on the one hand,
and the Placement Agent and any other Indemnified Person, on the other hand, in connection with the matters as to which such Liabilities
or Expenses relate, as well as any other relevant equitable considerations; provided that in no event shall the Company contribute less
than the amount necessary to ensure that all Indemnified Persons, in the aggregate, are not liable for any Liabilities and Expenses in
excess of the amount of commissions actually received by the Placement Agent pursuant to this Agreement. The relative fault shall be
determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or
alleged omission to state a material fact relates to information supplied by the Company on the one hand or the Placement Agent on the
other and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or
omission. The Company and the Placement Agent agree that it would not be just and equitable if contributions pursuant to this subsection
(D) were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations
referred to above in this subsection (D). For purposes of this paragraph, the relative benefits to the Company, on the one hand, and
to the Placement Agent on the other hand, of the matters contemplated by this Agreement shall be deemed to be in the same proportion
as: (a) the total value received by the Company in the Offering, whether or not such Offering is consummated, bears to (b) the commissions
paid to the Placement Agent under this Agreement. Notwithstanding the above, no person guilty of fraudulent misrepresentation within
the meaning of Section 11(f) of the Securities Act shall be entitled to contribution from a party who was not guilty of fraudulent misrepresentation.

 

E.
Limitation. The Company also agrees that no Indemnified Person shall have any liability (whether direct or indirect, in contract
or tort or otherwise) to the Company for or in connection with advice or services rendered or to be rendered by any Indemnified Person
pursuant to this Agreement, the transactions contemplated thereby or any Indemnified Person’s actions or inactions in connection
with any such advice, services or transactions, except to the extent that a court of competent jurisdiction has made a finding that Liabilities
(and related Expenses) of the Company have resulted exclusively from such Indemnified Person’s gross negligence or willful misconduct
in connection with any such advice, actions, inactions or services.

 

    	21

    	Progressive Care Inc.

    

 

F.
Survival. The advancement, reimbursement, indemnity and contribution obligations set forth in this Section 9 shall remain in full
force and effect regardless of any termination of, or the completion of any Indemnified Person’s services under or in connection
with, this Agreement.

 

	10.	Limitation
                                            of Dawson’s Liability to the Company.

 

Dawson
and the Company further agree that neither Dawson nor any of its affiliates or any of their respective officers, directors, controlling
persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act), employees or agents shall have any
liability to the Company, its security holders or creditors, or any person asserting claims on behalf of or in the right of the Company
(whether direct or indirect, in contract or tort, for an act of negligence or otherwise) for any losses, fees, damages, liabilities,
costs, expenses or equitable relief arising out of or relating to this Agreement or the Services rendered hereunder, except for losses,
fees, damages, liabilities, costs or expenses that arise out of or are based on any action of or failure to act by Dawson and that are
finally judicially determined to have resulted solely from the gross negligence or willful misconduct of Dawson.

 

	11.	Limitation
                                            of Engagement to the Company.

 

The
Company acknowledges that Dawson has been retained only by the Company, that Dawson is providing services hereunder as an independent
contractor (and not in any fiduciary or agency capacity) and that the Company’s engagement of Dawson is not deemed to be on behalf
of, and is not intended to confer rights upon, any shareholder, owner or partner of the Company or any other person not a party hereto
as against Dawson or any of its affiliates, or any of its or their respective officers, directors, controlling persons (within the meaning
of Section 15 of the Securities Act or Section 20 of the Exchange Act), employees or agents. Unless otherwise expressly agreed in writing
by Dawson, no one other than the Company is authorized to rely upon any statement or conduct of Dawson in connection with this Agreement.
The Company acknowledges that any recommendation or advice, written or oral, given by Dawson to the Company in connection with Dawson’s
engagement is intended solely for the benefit and use of the Company’s management and directors in considering a possible Offering,
and any such recommendation or advice is not on behalf of, and shall not confer any rights or remedies upon, any other person or be used
or relied upon for any other purpose. Dawson shall not have the authority to make any commitment binding on the Company. The Company,
in its sole discretion, shall have the right to reject any investor introduced to it by Dawson. The Company agrees that it will perform
and comply with the covenants and other obligations set forth in any purchase agreement and related transaction documents between the
Company and the Investors in the Offering, if any, and that Dawson will be entitled to rely on the representations, warranties, agreements
and covenants of the Company contained in any such purchase agreement and related transaction documents as if such representations, warranties,
agreements and covenants were made directly to Dawson by the Company, provided that no such representations, warranties, agreements and
covenants shall in any way limit or modify the representations, warranties, agreements and covenants set forth in this Agreement.

 

    	22

    	Progressive Care Inc.

    

 

	12.	Amendments
                                            and Waivers.

 

No
supplement, modification or waiver of this Agreement shall be binding unless executed in writing by the party to be bound thereby. The
failure of a party to exercise any right or remedy shall not be deemed or constitute a waiver of such right or remedy in the future.
No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (regardless
of whether similar), nor shall any such waiver be deemed or constitute a continuing waiver unless otherwise expressly provided.

 

	13.	Confidentiality.

 

In
the event of the consummation or public announcement of any Offering, Dawson shall have the right to disclose its participation in such
Offering, including, without limitation, the placement at its cost of “tombstone” advertisements in financial and other newspapers
and journals. Dawson agrees not to use any confidential information concerning the Company provided to Dawson by the Company for any
purposes other than those contemplated under this Agreement.

 

Dawson
acknowledges that it may be necessary for the Company during the Term, to disclose certain confidential and proprietary information (“Confidential
Information”) to Dawson, in order for Dawson to perform the Services pursuant to this Agreement. Dawson shall not disclose or use,
at any time either during or after the Term of this Agreement, for their own benefit or for the benefit of any third party, any Confidential
Information without the Company’s prior written permission except to the extent necessary to perform the Services on the Company’s
behalf. Confidential Information includes, without limitation:

 

(a) The
written, printed, graphic or electronically recorded materials furnished by the Company for Dawson to use;

 

(b) Any
written or tangible information stamped “confidential,” “proprietary” or with a similar legend or any information
that the Company makes reasonable efforts to maintain its secrecy;

 

    	23

    	Progressive Care Inc.

    

 

(c) Business,
research and development, regulatory and marketing plans, objectives and/or strategies, financial information, corporate initiatives,
contractual and business arrangements, customer lists, supplier lists, sales projections, product information, product launch plans,
regulatory submissions, pricing information of the Company and its affiliates;

 

(d) Information,
data, test results, patent applications, methodologies, operating procedures, trade secrets, design formulas, know-how, techniques, analyses,
technology, processes, protocols, specifications and instructions relating to the Company’s proprietary products, including safety
data and reference standards, investigators brochures, documents and reports, computer programs and inventories, discoveries and improvements
of any kind, sales projections, product information, pricing information of the Company and its affiliates;

 

(e) Information,
know-how, trade secrets, materials and tangible property belonging to customers and suppliers of the Company and other third parties
who have disclosed such confidential and proprietary information to the Company about whom Dawson gained knowledge as a result of providing
Services to the Company;

 

(f) Any
data, deliverables or other work product or information generated or developed by Dawson in connection with the performance of Services
under this Agreement; and

 

(g) Any
copies, extracts, notes, or summaries of any information described in clauses (a) through (f).

 

Notwithstanding
any of the foregoing, Confidential Information shall not include any information that:

 

(a) is
or becomes available in the public domain through no fault of, or act or failure to act on the part of Dawson;

 

(b) is
rightfully in Dawson’s possession at the time of disclosure by the Company; or

 

(c) is
obtained, after the Effective Date, by Dawson from any third party that is lawfully in possession of such Confidential Information and
not in violation of any contractual or legal obligation with respect to such Confidential Information.

 

9. At
any time upon request of the Company or upon termination of this Agreement, Dawson shall promptly deliver to the Company all Confidential
Information (and all copies thereof) and all other property furnished to Dawson by the Company.

 

    	24

    	Progressive Care Inc.

    

 

	14.	Headings.

 

The
headings of the various sections of this Agreement have been inserted for convenience of reference only and will not be deemed to be
part of this Agreement.

 

	15.	Counterparts.

 

This
Agreement may be executed in one or more counterparts and, if executed in more than one counterpart, the executed counterparts shall
each be deemed to be an original and all such counterparts shall together constitute one and the same instrument.

 

	16.	Severability.

 

In
case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality and
enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby.

 

	17.	Use
                                            of Information.

 

The
Company will furnish Dawson such written information as Dawson reasonably requests in connection with the performance of its services
hereunder. The Company understands, acknowledges and agrees that, in performing its services hereunder, Dawson will use and rely entirely
upon such information as well as publicly available information regarding the Company and other potential parties to an Offering and
that Dawson does not assume responsibility for independent verification of the accuracy or completeness of any information, whether publicly
available or otherwise furnished to it, concerning the Company or otherwise relevant to an Offering, including, without limitation, any
financial information, forecasts or projections considered by Dawson in connection with the provision of its services.

 

    	25

    	Progressive Care Inc.

    

 

	18.	Absence
                                            of Fiduciary Relationship.

 

The
Company acknowledges and agrees that: (a) the Placement Agent has been retained solely to act as Placement Agent in connection with the
sale of the Securities and that no fiduciary, advisory or agency relationship between the Company and the Placement Agent has been created
in respect of any of the transactions contemplated by this Agreement, irrespective of whether the Placement Agent has advised or is advising
the Company on other matters; (b) the price and other terms of the Securities set forth in this Agreement were established by the Company
following discussions and arms-length negotiations with the Placement Agent and the Company is capable of evaluating and understanding
and understands and accepts the terms, risks and conditions of the transactions contemplated by this Agreement; (c) it has been advised
that the Placement Agent and its affiliates are engaged in a broad range of transactions that may involve interests that differ from
those of the Company and that the Placement Agent has no obligation to disclose such interest and transactions to the Company by virtue
of any fiduciary, advisory or agency relationship; and (d) it has been advised that the Placement Agent is acting, in respect of the
transactions contemplated by this Agreement, solely for the benefit of the Placement Agent, and not on behalf of the Company.

 

	19.	Survival
                                            Of Indemnities, Representations, Warranties, Etc.

 

The
respective indemnities, covenants, agreements, representations, warranties and other statements of the Company and Placement Agent, as
set forth in this Agreement or made by them respectively, pursuant to this Agreement, shall remain in full force and effect, regardless
of any investigation made by or on behalf of the Placement Agents, the Company, the Purchasers or any person controlling any of them
and shall survive delivery of and payment for the Securities. Notwithstanding any termination of this Agreement, including without limitation
any termination pursuant to Section 5, the payment, reimbursement, indemnity, contribution and advancement agreements contained in Sections
2, 5, 9, and 10, respectively, and the Company’s covenants, representations, and warranties set forth in this Agreement shall not
terminate and shall remain in full force and effect at all times. The indemnity and contribution provisions contained in Section 9 and
the covenants, warranties and representations of the Company contained in this Agreement shall remain operative and in full force and
effect regardless of (i) any termination of this Agreement, (ii) any investigation made by or on behalf of any Placement Agent, any person
who controls any Placement Agent within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act or any
affiliate of any Placement Agent, or by or on behalf of the Company, its directors or officers or any person who controls the Company
within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act, and (iii) the issuance and delivery
of the Securities. The Company and Placement Agent agree to notify each other of the commencement of any Proceeding against either of
them promptly, and, in the case of the Company, against any of the Company’s officers or directors in connection with the issuance
and sale of the Securities.

 

    	26

    	Progressive Care Inc.

    

 

	20.	Governing
                                            Law.

 

This
Agreement shall be governed by and construed in accordance with the laws of the State of Florida applicable to agreements made and to
be fully performed therein. Any disputes that arise under this Agreement, even after the termination of this Agreement, will be heard
only in the state or federal courts located in the Broward County, State of Florida. The parties hereto expressly agree to submit themselves
to the jurisdiction of the foregoing courts in the Broward County, State of Florida. The parties hereto expressly waive any rights they
may have to contest the jurisdiction, venue or authority of any court sitting in the State of Florida.

 

	21.	Notices.

 

All
communications hereunder shall be in writing and shall be mailed, hand delivered or faxed and confirmed to the parties hereto as follows:

 

If
to the Company to the address set forth above, attn: Chief Executive Officer

 

If
to the Placement Agent:

 

Dawson
James Securities, Inc.

1
North Federal Highway – 5th Floor

Boca
Raton, FL 33432

Attention:
Chief Executive Officer

 

Any
party hereto may change the address for receipt of communications by giving written notice to the others.

 

	22.	Miscellaneous.

 

This
Agreement shall not be modified or amended except in writing signed by Dawson and the Company. This Agreement shall be binding upon and
inure to the benefit of both Dawson and the Company and their respective assigns, successors, and legal representatives. This Agreement
constitutes the entire agreement of Dawson and the Company, and supersedes any prior agreements, with respect to the subject matter hereof.
If any provision of this Agreement is determined to be invalid or unenforceable in any respect, such determination will not affect such
provision in any other respect, and the remainder of this Agreement shall remain in full force and effect. This Agreement may be executed
in counterparts (including facsimile or .pdf counterparts), each of which shall be deemed an original but all of which together shall
constitute one and the same instrument.

 

	23.	Successors.

 

This
Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees, officers and directors
and controlling persons referred to in Section 9 hereof, and to their respective successors, and personal representative, and, except
as set forth in Section 9 of this Agreement, no other person will have any right or obligation hereunder or be considered a third-party
beneficiary hereunder.

 

	24.	Partial
                                            Unenforceability.

 

The
invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability
of any other section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement is for any reason determined
to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to
make it valid and enforceable.

 

	25.	General
                                            Provisions.

 

The
Company acknowledges that in connection with the Offering of the Securities the Placement Agent: (i) has acted at arms-length, are not
agents of, and owe no fiduciary duties to the Company or any other person, (ii) owes the Company only those duties and obligations set
forth in this Agreement and (iii) may have interests that differ from those of the Company. The Company waives to the full extent permitted
by applicable law any claims it may have against the Placement Agent arising from an alleged breach of fiduciary duty in connection with
the Offering.

 

    	27

    	Progressive Care Inc.

    

 

In
acknowledgment that the foregoing correctly sets forth the understanding reached by Dawson and the Company, and intending to be legally
bound, please sign in the space provided below, whereupon this letter shall constitute a binding Agreement as of the date executed.

 

	Very
    truly yours,	 
	 	 
	Progressive
    Care, Inc.	 
	 	 
	By:	/s/
    Alan Jay Weisberg	 
	Name:	Alan
    Jay Weisberg	 
	Title:	Chief
    Executive Officer       	 

 

Agreed
and accepted as of the date first above written.

 

DAWSON
JAMES SECURITIES, INC.

 

	By:	/s/
    Robert D. Keyser, Jr.	 
	Name:	Robert
    D. Keyser, Jr.	 
	Title:	Chief
    Executive Officer	 

 

    	28

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]